Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Biomed Biotechnol. 2010;2010. pii: 479364. doi: 10.1155/2010/479364. Epub 2010 Jul 29.

Molecular and therapeutic potential and toxicity of valproic acid.

Author information

  • 1Laboratoire de Biologie Moléculaire et Cellulaire du Cancer (LBMCC), Fondation de Recherche Cancer et Sang, Hôpital Kirchberg, Kirchberg 2540, Luxembourg.

Abstract

Valproic acid (VPA), a branched short-chain fatty acid, is widely used as an antiepileptic drug and a mood stabilizer. Antiepileptic properties have been attributed to inhibition of Gamma Amino Butyrate (GABA) transaminobutyrate and of ion channels. VPA was recently classified among the Histone Deacetylase Inhibitors, acting directly at the level of gene transcription by inhibiting histone deacetylation and making transcription sites more accessible. VPA is a widely used drug, particularly for children suffering from epilepsy. Due to the increasing number of clinical trials involving VPA, and interesting results obtained, this molecule will be implicated in an increasing number of therapies. However side effects of VPA are substantially described in the literature whereas they are poorly discussed in articles focusing on its therapeutic use. This paper aims to give an overview of the different clinical-trials involving VPA and its side effects encountered during treatment as well as its molecular properties.

PMID:
20798865
[PubMed - indexed for MEDLINE]
PMCID:
PMC2926634
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk